Obese T2DM with nephropathy
Conditions
Interventions
Addition of canagliflozin (100mg once daily) to standard therapy for one year.
Sponsors
Division of Nephrology, Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Obtained written informed consent 2) Patients who eligible to following criteria; ACR > 30mg/gCr, eGFR > 45ml/min/1.73m2, BMI > 25 Kg/m2 or waist circumference > 85cm (men) 90cm (women), HbA1c 6.5-9.0% (NGSP) 3) Patients who wasnot prescribed SGLT2 inhibitors for more than 3 months at entry. 4) Patients who can visit the hospital throughout the study.
Exclusion criteria
Exclusion criteria: 1) HbA1C >9.0% 2) Allergy to canagliflozin 3) Severe ketoacidosis or diabetic coma 4) severe infection, operation, and trauma 5)T1DM 6) Moderate to severe renal disfuction (eGFR <45ml/min/1.73m2) 7) Heart failure (NYHA IV) 8) possibility of hypoglycemia by canagliflozine such as hypopituitarism, adrenal insuficiency, excessive exercise, malnutition, excess alcohol intake. 9) Dehydration 10) severe liver disfunction (AST and ALT > 5 x normal range of the hospital) 11) Age more than 70 years 12) Age less than 20 years 13) Pregnant or breastfeeding mother 14) patients who was regarded as uneligible by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of eGFR slope | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood evaluation: HbA1c, eGFR, serum Cr, cystatin C, Uriva acid, T-chol, HDL-chol, TG Urine evaluation: ACR, 24hCCr, Urine volume, Na, K, Cl, L-FABP, B2-Mg, NAG, glucose and protein Blood pressure at office | — |
Countries
Japan
Contacts
Public ContactShuichi Tsuruoka
Nippon Medical School Division of Nephrology
Outcome results
None listed